New nasal spray offers hope for depression patients Who've tried everything else

NCT ID NCT07053345

Summary

This study is testing whether esketamine nasal spray can help reduce depression symptoms in Korean patients whose depression hasn't improved with at least two standard antidepressant medications. Researchers will measure changes in depression scores over 4 weeks of treatment. The study is open-label, meaning everyone receives the nasal spray, and it focuses specifically on the Korean population.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSIVE DISORDER, TREATMENT-RESISTANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Asan Medical Center

    RECRUITING

    Seoul, 05505, South Korea

  • Cha Ilsan Medical Center

    RECRUITING

    Goyang Si Gyeonggi Do, 10414, South Korea

  • Kangbuk Samsung Hospital

    RECRUITING

    Seoul, 03181, South Korea

  • Kyung Hee University Hospital

    RECRUITING

    Seoul, 130 050, South Korea

  • Samsung Medical Center

    RECRUITING

    Seoul, 06351, South Korea

  • Wonkwang University Hospital

    RECRUITING

    Iksan, 570 711, South Korea

Conditions

Explore the condition pages connected to this study.